- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Newsletter: December 2019
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
WuXi Biologic’ subsidiary WuXi Vaccines, engaged in human vaccine Contract Development & Manufacturing Organization (CDMO) business, will invest $240 million to build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent signed by WuXi Vaccines earlier this year. Read More
Partner News
Biologic Products DNA to IND Timeline in 9 Months – Yes It Can Be Done! Read More
WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development Read More
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development Read More
Antibody Drug Conjugate / Bioconjugates
Antibody Drug Conjugate (ADC) Development and Manufacturing Challenges & Solutions Read More
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing Read More
WuXiBody™ Bispecific Antibody News
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability Read More
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics Read More
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Read More
WuXiUP™ Platform News
Is Continuous Biomanufacturing a Good Fit for Your Process? Read More
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity Read More
Resources
From Concept to Market – Unique approaches in Biomanufacturing (Webinar)
Advanced Process Development Using Automated Micro Bioreactors Shortens Timelines & Provides Process Solutions for a Rapid Scale Up (Webinar)
Scale-Out Plus Single-Use Can Multiply Yields (Article)
Capacity Strategies: The Strategies Behind Choosing Between Large-Scale and Single-Use Investments (Article)
Viral Safety in Biomanufacturing (Video)
Ask the Expert Continuous Manufacturing (Article)
Scale-Out vs. Scale-Up GMP Manufacturing (Article)
WuXi Biologics Publications (Archive)
WuXi Biologics Perspectives (Archive)
Awards and Achievements
WuXi Biologics wins 2019 CMO Leadership Awards in all six core categories Read More
WuXi Biologics receives “Asia’s Best CMO of 2018” award from IMAPAC Read More
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?